From:  Safety and efficacy of non-medical switch from innovator to generic tofacitinib: a 3-month observational study in rheumatoid arthritis patients

 Comparison of disease activity before and after switching from innovator to generic tofacitinib during the 3-month follow-up.

CategoryBaseline3 months post-switchChanges post-switchp-value
PGA12.00 (10.00–16.00)13.50 (10.00–20.00)0.00 (−1.00–2.00)0.133
DAS28-ESR2.17 (1.58–2.77)2.45 (1.77–2.80)0.10 (−0.10–0.20)0.141
ESR35.00 (22.00–46.00)32.00 (24.75–47.00)−2.00 (−6.00–3.25)0.333
CRP2.00 (1.18–4.90)2.81 (1.29–6.00)0.04 (−0.21–0.78)0.167
SDAI2.60 (2.10–4.75)2.85 (2.27–6.40)0.05 (−0.10–0.12)0.546
CDAI2.00 (1.53–3.00)2.00 (0.98–3.10)0.00 (0.00–0.13)0.278
Changes in DAS28-ESR
≥ 0.6*, n (%)--6 (16.7%)-
≥ 1.2, n (%)--1 (2.8%)-
Return to article view

Numbers are medians (interquartile ranges) unless otherwise stated (%). CDAI: clinical disease activity index; CRP: C-reactive protein; DAS28-ESR: Disease Activity Score-28 erythrocyte sedimentation rate; PGA: patient global assessment; SDAI: simplified disease activity index. *Indicates none with DAS28-ESR ≥ 3.2 at 3 months post-switch.